{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T12:21:47Z","timestamp":1648642907204},"reference-count":5,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2022,2,1]]},"DOI":"10.1001\/jamadermatol.2021.4449","type":"journal-article","created":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T16:34:42Z","timestamp":1640190882000},"page":"218","source":"Crossref","is-referenced-by-count":0,"title":["Chilblains and COVID-19\u2014An Update on the Complexities of Interpreting Antibody Test Results, the Role of Interferon \u03b1, and COVID-19 Vaccines\u2014Reply"],"prefix":"10.1001","volume":"158","author":[{"given":"Patrick E.","family":"McCleskey","sequence":"first","affiliation":[{"name":"Department of Dermatology, The Permanente Medical Group, Northern California, Oakland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amara","family":"Lieberman","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Permanente Medical Group, Northern California, Oakland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa J.","family":"Herrinton","sequence":"additional","affiliation":[{"name":"Division of Research, Oakland, California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"8","key":"dlr210008r1","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/jamadermatol.2021.2120","article-title":"Epidemiologic analysis of chilblains cohorts before and during the COVID-19 pandemic.","volume":"157","author":"McCleskey","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"3","key":"dlr210008r2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/dermatopathology7030010","article-title":"Type I interferon signature in chilblain-like lesions associated with the COVID-19 pandemic.","volume":"7","author":"Aschoff","year":"2020","journal-title":"Dermatopathology (Basel)"},{"issue":"4","key":"dlr210008r3","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.jaad.2020.06.1018","article-title":"New insights in COVID-19-associated chilblains: a comparative study with chilblain lupus erythematosus.","volume":"83","author":"Battesti","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"dlr210008r4","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.mayocp.2021.01.009","article-title":"Pernio (chilblains), SARS-CoV-2, and COVID toes unified through cutaneous and systemic mechanisms.","volume":"96","author":"Cappel","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"dlr210008r5","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/bjd.v183.5","article-title":"Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on polymerase chain reaction and serology testing.","volume":"183","author":"Le Cleach","year":"2020","journal-title":"Br J Dermatol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2787465\/jamadermatology_mccleskey_2021_lr_210008_1643827841.48125.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T16:07:14Z","timestamp":1645027634000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2787465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,1]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2021.4449","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,1]]}}}